Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Web-based Staple Help You Can Trust - 2'Senseless violence' erupts at Christmas tree lighting; 4 injured
- 3Five killed in Israeli air strikes on tents near Khan Younis, medics say
- 4FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- 5The beauty advent calendar boom is here. Sephora kids are all in.
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Vote In favor of Your #1 Method for diminishing Pressure
- Flu concerns grow in US as UK sees more cases among kids
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- Building an Individual Brand: Illustrations from Powerhouses
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Instructions to Boost Your True capacity with a Brain research Degree
- Vote in favor of the subject that you see as generally captivating and intelligent!
